Inhibition of melanoma metastases by fenofibrate

Archives of Dermatological Research

Volumn 296, Issue 2, 2004, Pages 54-58

  Grabacka, Maja ^a,b   Placha, Wojciech ^c   Plonka, Przemyslaw M ^a   Pajak, Stanislawa ^a   Urbanska, Krystyna ^a   Laidler, Piotr ^c   Slominski, Andrzej ^d  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Temple University   (United States)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Chemoprevention; Fenofibrate; Metastases; PPAR; Syrian hamster; Transplantable melanoma

Indexed keywords

FENOFIBRATE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IN VIVO STUDY; LIGAND BINDING; LUNG METASTASIS; MELANOMA; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYRIAN HAMSTER; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CRICETINAE; FEMALE; LIGANDS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MESOCRICETUS; PPAR ALPHA; PROCETOFEN; RNA, MESSENGER; RNA, NEOPLASM;

EID: 3543138832     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-004-0479-y     Document Type: Article

References (54)

1. Aranega A, Gonzalez FJ, Aranega AE, Muros MA, Fernandez JE, Velez C, Prados J, Alvarez L (1991) Effects of fibric acid derivatives on accumulation of actin in myocardiocytes. Int J Cardiol 33:47-54
2. Aranega AE, Velez MC, Gonzalez FJ, Melguizo C, Prados JC, Aranega A (1995) Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives. Eur J Morphol 33:421-431
3. Blane GF (1989) Review of European clinical experience with fenofibrate. Cardiology 76 [Suppl 1]:1-10
4. Bomirski A, Slominski A, Bigda J (1988) The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev 7:95-118
5. Cardones AR, Murakami, T, Hwang ST (2003) CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta (1) integrin. Cancer Res 63:6751-6757
6. Chinetti G, Fruchart JC, Staels B (2001) Peroxisome proliferator- activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 90 [Suppl 3]:125-132
7. Chomczynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
8. Dellavalle RP, Nicholas MK, Schilling LM (2003) Melanoma chemoprevention: a role for statins and fibrates? Am J Ther 10:203-210
9. Demierre MF, Nathanson (2003) Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 21:158-165
10. Downs JR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
11. Elstner E, Muller C, Koshizuka K, Williamson E, Park D, Asou H, Shintaku P, Said JW., Heber D, Koeffier HP (1998) Ligands for peroxisome proliferator-activated receptor α and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95:8806-8811
12. Engebraaten O, Bjerkvig R, Berens ME (1991) Effects of alkyl-lysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro. Cancer Res 51:1713-1719
13. Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121-138
14. Farina HG, Bublik DR, Alonso DF, Gomez DE (2002) Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19:551-559
15. Frishman WH, Rapier RC (1989) Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am 73:437-448
16. Gonzalez F, Peters JM, Cattley RC (1990) Review: mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor α. J Natl Cancer Inst 90:1702-1709
17. Guan RJ, Ford JL, Fu YN, Li YZ, Shaw LM, Pardee AB (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 60:749-755
18. Hyrc K, Kapiszewska M, Cieszka K (1985) Differences in the electrophoretic mobilities of pigmented and non-pigmented melanoma cells. In: Schutt W, Klinkmann H (eds) Cell electrophoresis. Walter de Gruyter, Berlin New York, pp 451-457
19. Jakobisiak M, Golab J (2003) Potential antitumor effects of statins (review). Int J Oncol 23:1055-1069
20. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, Katoh A (1993) Metastasis of B16 F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314-324
21. Keelan JA, Sato T A, Marvin KW, Lander J, Gilmour RS, Mitchell M. (1999) 15-Deoxy-Δ12,14-prostaglandin J2, a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 262:579-585
22. Kier AB, Parker MT, Schroeder F (1988) Local and metastatic tumor growth and membrane properties of LM fibroblasts in athymic (nude) mice. Biochim Biophys Acta 938:434-446
23. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans DM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774
24. Kort WJ, Hulsmann WC, Stehman TE (1989) Modulation of metastatic ability by inhibition of cholesterol synthesis. Clin Exp Metastasis 7:517-523
25. Kroetz D, Yook P, Costet P, Pineau T (1998) Peroxisome proliferator-activated receptor α (PPAR α) controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 273:31581-31589
26. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227:680-685
27. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150:179-185
28. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB (1991) Crystallographic analysis of interaction of the glucocorticoid receptor with DNA. Nature 352:497-505
29. Lukiewicz S, Pilas B, Nowicka J, Cieszka K, Gurbiel R (1981) Molecular and cellular basis of different radiosensitivity in pigmented and nonpigmented hamster melanoma cells. In: Seiji H (ed) Pigment cell. Phenotypic expression in pigment cells. Proceedings of the XIth International Pigment Cell Conference, Sendai, Japan. University of Tokyo Press, Tokyo, pp 23-29
30. Martin G, Duez H, Blanquart C, BerezowskiV, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B (2001) Statin-induced inhibition of the Rho signalling pathway activates PPAR α and induces HDL-apoAI. J Clin Invest 107:1423-1432
31. McIntosh TJ (1978) The effect of cholesterol on the structure of phosphatidylcholine bilayers. Biochim Biophys Acta 513:43-58
32. Mossner R, Schulz U, Kruger U, Middel P, Shinner S, Fuzesi L, Neumann C, Reich K (2002) Agonists of peroxisome proliferator-activated receptors γ inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576-582
33. Neitzel LT, Neitzel CD, Magee KL, Malafe MP (1999) Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 6:70-74
34. Nyguist DA, Watanabe I, Melnykovych G (1992) Alkyllysophospholipid influenced melanoma cell morphology is associated with decreased attachment to basement membrane. Ukr Biokhim Zh 64:76-85
35. Pineau T, Hudgins RW, Liu L, Chen L, Sher T, Gonzalez FJ, Samid D (1996) Activation of human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52:659-667
36. Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003) The effect of PPAR γ ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447-456
37. Rival Y, Benéteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau J-F, Junquéro D, Colpaert FC, Delhon A (2002) PPARct and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143-151
38. Rog T, Pasenkiewicz-Gierula M (2001) Cholesterol effects on the phospholipid condensation and packing in the bilayer: a molecular simulation study. FEBS Lett 502:68-71
39. Romanowska-Dixon B, Urbanska K, Elas M, Pajak S, Zygulska-Mach H, Miodonski A (2001) Angiomorphology of the pigmented Bomirski melanoma growing in hamster eye. Ann Anat 183:559-565
40. Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase inhibitors: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652
41. Rubins HB, Robins SJ, Collins CL, Anderson JW, Elam MB, Faas FH, Linares EJ, Schaeffer EJ, Schechtman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study. N Engl J Med 341:410-418
42. Schreck R (1936) Further quantitative methods for the study of transplantable tumors. The growth of R39 sarcoma and Brown-Pierce carcinomas. Am J Cancer 28:345-351
43. Schroeder F, Gardiner JM (1984) Membrane lipids and enzymes of high- and low-metastatic B16 melanoma variants. Cancer Res 44:3262-3269
44. Scislowski PWD, Slominski A, Bomirski A, Zydowo B (1985) Metabolic characterization of three hamster melanoma variants. Neoplasma 32:593-598
45. Sherbet GV (1989) Membrane fluidity and cancer metastasis. Exp Cell Biol 57:198-205
46. Singh RP, Kumar R, Kapur N (2003) Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis. J Environ Pathol Toxicol Oncol 22:75-92
47. Siperstein MD (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25:1462-1468
48. Siperstein MD, Fagan VM (1964) Deletion of the cholesterolnegative feedback system in liver tumors. Cancer Res 24:1108-1115
49. Slominski A, Paus R (1993) Bomirski melanomas: a versatile and powerful model for pigment cell and melanoma research (review). Int J Oncol 2:221-228
50. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC (2001) Malignant melanoma. An update. Arch Pathol Lab Med 125:1295-1306
51. Storme G, Berdel WE, Van Blittersvijk WJ, Bruynel EA, De Bruyne GK, Mareel MM (1985) Antiinvasive effect of racemic 1-O octadecyl-2-O-methylglycero- 3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res 45:351-357
52. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, Mishal Z, Soria J, Li H, Soria C (2003) Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60:810-819
53. Vereb G, Matko J, Vamosi G, Ibrahim SM, Magyar E, Varga S, Szollosi J, Jenei A, Gaspar R Jr, Waldmann TA, Damjanovich S (2000) Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc Natl Acad Sci U S A 97:6013-6018
54. Wulfert E, Boissard G, Legendre C, Baron C (1981) Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity. Artery 9:120-131